An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
about
Potential approaches to the treatment of Ewing's sarcomaDevelopment of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imagingTKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CMLNew therapeutic targets in soft tissue sarcoma.Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.Targeted therapies for advanced Ewing sarcoma family of tumors.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionA Class of Diacylglycerol Acyltransferase 1 Inhibitors Identified by a Combination of Phenotypic High-throughput Screening, Genomics, and GeneticsMolecular profiling of childhood cancer: Biomarkers and novel therapiesTargeting protein kinases to reverse multidrug resistance in sarcoma.Systems biology analysis of protein-drug interactions.Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.Building and exploring an integrated human kinase network: global organization and medical entry points.CINSARC: a new look into an old concept gives hope for new treatments for synovial sarcomas.Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporterPast, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
P2860
Q28072744-229C32BA-E180-4C5C-909B-68C7CE22C7E9Q28538391-66F80FAE-EB1D-494C-92F9-85B3EAFD2CE1Q30357188-B97EFF85-0517-4BD1-889E-56D606757E41Q34267924-005CE05A-A40A-4ED1-8AE6-F427B9D8DF08Q34797680-A7B735FB-27D5-4F00-BE12-6D4E76128304Q35589492-0128E4EB-9D88-4F76-9121-F9935DA2A19FQ35767389-AD76AE5E-EC72-4727-ABE6-3F56CA7952FBQ36080184-867C58A1-27FA-4846-A3B8-231419F8C6B9Q36250783-62F68B40-8F80-4727-94F2-849377DEC389Q36527950-6BB32609-5D8A-4B93-84AF-9A7643D7E42FQ37972867-DBCDDCCF-51B9-4E12-BBEE-BD07D4B18EBFQ39101609-AD9C0F44-005C-444A-8750-B59A0623DD7BQ39215261-B9CE423E-2393-49F2-ACEE-01DE51284109Q40033130-BBB2F752-4619-4F54-A522-DC3F478B9931Q40180908-81F41165-D557-4EB1-BAFE-59CE26EA383CQ42212236-DCB511AB-7D6C-4339-977B-069B9FB57D6EQ55362356-8B9CBA54-2473-4BBD-BE7C-7189D4F8A4D3
P2860
An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
An integrated chemical biology ...... ion of Aurora kinases A and B.
@en
An integrated chemical biology ...... ion of Aurora kinases A and B.
@nl
type
label
An integrated chemical biology ...... ion of Aurora kinases A and B.
@en
An integrated chemical biology ...... ion of Aurora kinases A and B.
@nl
prefLabel
An integrated chemical biology ...... ion of Aurora kinases A and B.
@en
An integrated chemical biology ...... ion of Aurora kinases A and B.
@nl
P2093
P50
P1476
An integrated chemical biology ...... tion of Aurora kinases A and B
@en
P2093
Andrej Lissat
Georg E Winter
Keiryn L Bennett
Markus K Müllner
Udo Kontny
P304
P356
10.1158/1535-7163.MCT-11-0100
P577
2011-07-18T00:00:00Z